Compare AP & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AP | CVM |
|---|---|---|
| Founded | 1929 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 53.1M |
| IPO Year | N/A | 1987 |
| Metric | AP | CVM |
|---|---|---|
| Price | $2.74 | $6.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 193.2K | 54.9K |
| Earning Date | 11-12-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $426,314,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.20 | N/A |
| 52 Week Low | $1.75 | $1.98 |
| 52 Week High | $3.99 | $32.70 |
| Indicator | AP | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 44.99 |
| Support Level | $2.46 | $6.00 |
| Resistance Level | $2.99 | $7.80 |
| Average True Range (ATR) | 0.30 | 0.50 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 77.83 | 48.33 |
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.